It is our pleasure to announce the appointment of stem cell therapy pioneer Martin McGlynn to the Board of Directors of Regenerative Medicine Foundation.

Mr. McGlynn has long been at the forefront of development in the area of regenerative medicine, having served as Chief Executive Officer of StemCells, Inc., from 2001 to 2016.

“Martin McGlynn is an ideal addition to our Board,” said Bernard Siegel, Executive Director, of the Regenerative Medicine Foundation and Founder of the World Stem Cell Summit. “His extensive history both in industry and in advocacy, with decades of contributing to the development of regenerative medicine platforms will add both practical knowledge and long term vision in support of our mission to unite groups committed to expanding the frontiers of regenerative medicine.”

“I have always admired the work of the RMF and their commitment to wide-ranging strategic projects involving researchers, patient advocates, policy groups and the public at large,” said Mr. McGlynn. “I look forward to supporting these projects at this stage in the expansion of the RMF as it builds engagement surrounding what will clearly become transformative therapies. The nascent field of regenerative medicine requires that we bring together multiple interest groups to realize its potential in addressing humanitarian needs.”

Mr. McGlynn served as Chief Executive Officer, President and Director of StemCells, Inc. as the company developed applications for cell therapy platform technologies in multiple therapeutic areas and brought neural stem cell therapy in cervical spinal cord injury into Phase 2 clinical trials, conducting a ground-breaking US clinical trial with a well-established safety profile. Mr. McGlynn has also held positions of leadership with non-profit advocacy groups in the area of regenerative medicine. His global experience in industry includes roles at Becton Dickinson, Abbott Labs, Anaquest and Pharmadigm. He has served as Member of the Board of Directors of the Confederation of Irish Industries as well as on the Board of the Pharmaceutical Manufacturers Association of Canada. Mr. McGlynn is a graduate of University College Dublin and pursued advanced studies at the Irish Institute of Industrial Engineering and the University of Birmingham, England.